Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSIBOOST 2: Cobicistat Boosting of Osimertinib in NSCLC
NCT05748093Phase 4Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cobicistat in non-small cell lung cancer (NSCLC), sponsored by Maastricht University Medical Center+. Started Apr 2024; status: recruiting.
02
Drugs
cobicistat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05748093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05748093.